-
Mashup Score: 1
A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 3
A team of investigators has found that nomacopan, a recombinant biologic derived from blood-feeding ticks, may be an option for the treatment of allergic eye disease due to its ability to down-regulate the LTB4/C5 pathways in experimental allergy conjunctivitis.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Study focuses on potential biologic to treat #allergic #eye disease. Learn more: https://t.co/RwyrWUZ4JE #Ophthalmology #Clinical #Ocular #OcularAllergy #Therapeutics https://t.co/5cxYOdf13D
-
-
Mashup Score: 2
A team of investigators has found that nomacopan, a recombinant biologic derived from blood-feeding ticks, may be an option for the treatment of allergic eye disease due to its ability to down-regulate the LTB4/C5 pathways in experimental allergy conjunctivitis.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Study focuses on potential biologic to treat #allergic #eye disease. https://t.co/vkmdyZIKjL #Ophthalmology #Clinical #Ocular #OcularAllergy #Therapeutics https://t.co/kl0inqotwp
-
-
Mashup Score: 5Seasonal allergies: Common trigger for dry eye flares - 2 year(s) ago
Short-term steroid use can alleviate patient discomfort.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Seasonal #allergies: Common trigger for dry eye flares. https://t.co/VCHjaElGEk @DZEyeMD #Ophthalmology #DryEyeDisease #DED #Clinical #Cornea #Ocular #OcularAllergy https://t.co/Kne7e977om
-
-
Mashup Score: 0Webinar Registration - Evolve Medical Education - 2 year(s) ago
Allergic disease may affect as many as 50 million Americans, and most people with allergies are likely to have an ocular component. Tune in for an expert panel discussion on ocular allergy classification and diagnosis, as well as a review of current and future treatments. The faculty will also discuss the correlation between dry eye disease and ocular…
Source: evolvemeded.comCategories: Latest Headlines, OphthalmologyTweet-
New CE for the New Year! #OcularAllergy: Incorporating Current and Emerging Treatment Options into Practice. [COPE CE Offered & Approved for AMA Category 1 Credits™] Register here: https://t.co/Df2MtY7h8F https://t.co/mdE7wYBto2
-
-
Mashup Score: 2The sky is the limit for allergy pipeline - 3 year(s) ago
Growing patient pool is driving clinical trial investment.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
A growing patient pool needing greater treatment options for ocular allergy is driving clinical trial investment —in a number of areas. #ocularallergy #ophthalmology #conjunctivitis https://t.co/lkOkoUEnAX
-
-
Mashup Score: 2The sky is the limit for allergy pipeline - 3 year(s) ago
Growing patient pool is driving clinical trial investment.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
A growing patient pool needing greater treatment options for ocular allergy is driving clinical trial investment —in a number of areas. #ocularallergy #ophthalmology #conjunctivitis https://t.co/iM7IjTZy7t
-
-
Mashup Score: 2The sky is the limit for allergy pipeline - 3 year(s) ago
Growing patient pool is driving clinical trial investment.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
A growing patient pool needing greater treatment options for ocular allergy is driving clinical trial investment —in a number of areas. #ocularallergy #ophthalmology #conjunctivitis https://t.co/Y7QX8ft4Fw
-
-
Mashup Score: 3The sky is the limit for allergy pipeline - 3 year(s) ago
Growing patient pool is driving clinical trial investment.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
A growing patient pool needing greater treatment options for ocular allergy is driving clinical trial investment —in a number of areas. #ocularallergy #ophthalmology #conjunctivitis https://t.co/TuvPPDHv2D
-
-
Mashup Score: 2The sky is the limit for allergy pipeline - 3 year(s) ago
Growing patient pool is driving clinical trial investment.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
A growing patient pool in need of greater treatment options for ocular allergy is driving clinical trial investment —in a number of areas. #ocularallergy #ophthalmology #conjunctivitis https://t.co/NRBPvwZx0s
-
A second #FDA indication for the treatment of #allergic conjunctivitis proves promising for patient relief Watch here: https://t.co/6Hpmsf48Nl #Ophthalmology #ASCRS22 #ascrs2022 #clinical #ophthotwitter #ocularallergy #ocular https://t.co/hW5Ekor8ya